This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EARS Auris Medical (EARS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesTrendsBuy This Stock About Auris Medical Stock (NASDAQ:EARS) 30 days 90 days 365 days Advanced Chart Get Auris Medical alerts:Sign Up Key Stats Today's Range$0.30▼$0.4350-Day Range$2.25▼$3.2752-Week Range$0.73▼$6.60Volume830,271 shsAverage Volume3.10 million shsMarket Capitalization$3.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAuris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.Read More… Receive EARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address EARS Stock News HeadlinesClinical cases of drug-resistant fungus Candida auris continue to rise in LouisianaMay 16 at 6:18 AM | msn.comDrug-resistant fungus Candida auris reported in these 17 statesMay 13, 2025 | msn.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 17, 2025 | Altimetry (Ad)Drug-resistant fungus a growing concern in health care settingsMay 13, 2025 | msn.com'Drug-resistant' fungal infection once 'rarely detected' now rising in EnglandApril 2, 2025 | mirror.co.ukHealth alert as UK hospital outbreaks linked to 'rapidly emerging' fungal infectionApril 2, 2025 | msn.comUKHSA reports 'previously rarely detected' fungal infection is 'rapidly emerging' in EnglandApril 1, 2025 | msn.comUKHSA issues warning of 'rapidly emerging' fungal infection in EnglandApril 1, 2025 | msn.comSee More Headlines EARS Stock Analysis - Frequently Asked Questions How were Auris Medical's earnings last quarter? Auris Medical Holding Ltd. (NASDAQ:EARS) posted its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the consensus estimate of ($2.80) by $1.60. When did Auris Medical's stock split? Auris Medical's stock reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Auris Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXDW), Novavax (NVAX), OPKO Health (OPK), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN) and Rigel Pharmaceuticals (RIGL). Company Calendar Last Earnings5/11/2017Today5/17/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EARS CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950FaxN/AEmployees132,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio3.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.57 per share Price / Book0.19Miscellaneous Outstanding Shares11,417,000Free FloatN/AMarket Cap$3.43 million OptionableNot Optionable Beta1.17 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:EARS) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Auris Medical Holding Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Auris Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.